The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 19, 2011

Filed:

Feb. 29, 2008
Applicants:

Jack Nguyen, San Francisco, CA (US);

Gregory T. Went, Mill Valley, CA (US);

Paul Spence, Mill, CA (US);

Timothy J. Fultz, Pleasant Hill, CA (US);

David Chernoff, San Rafael, CA (US);

Terry L. Burkoth, Palo Alto, CA (US);

Rowan Chapman, Burlingame, CA (US);

Mickey S. Urdea, Alamo, CA (US);

Inventors:

Jack Nguyen, San Francisco, CA (US);

Gregory T. Went, Mill Valley, CA (US);

Paul Spence, Mill, CA (US);

Timothy J. Fultz, Pleasant Hill, CA (US);

David Chernoff, San Rafael, CA (US);

Terry L. Burkoth, Palo Alto, CA (US);

Rowan Chapman, Burlingame, CA (US);

Mickey S. Urdea, Alamo, CA (US);

Assignee:

Adamas Pharmaceuticals, Inc., Emeryville, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/7056 (2006.01); A61K 31/351 (2006.01); A61K 31/215 (2006.01); A61K 31/196 (2006.01); A61K 31/195 (2006.01); A61K 31/131 (2006.01); C07H 19/056 (2006.01); C07D 309/28 (2006.01); C07C 69/75 (2006.01); C07C 61/22 (2006.01); C07C 229/48 (2006.01); C07C 211/38 (2006.01);
U.S. Cl.
CPC ...
Abstract

Kits comprising an M2 inhibitor selected from amantadine and rimantadine; ribavirin, and a neuraminidase inhibitor (NAi) in an amount that is antivirally effective in the combination, an oral dosage form containing 75-250 mg of the M2 inhibitor, an oral dosage form comprising 100-400 mg of ribavirin and a neuraminidase inhibitor are provided for the treatment of influenza. Some embodiments of the kits comprise an oral dosage form containing 75-250 mg of the M2 inhibitor, an oral dosage form comprising 100-400 mg of ribavirin, and a neuraminidase inhibitor.


Find Patent Forward Citations

Loading…